Global Furmonertinib Mesylate Market Growth 2026-2032
The global Furmonertinib Mesylate market size is predicted to grow from US$ 923 million in 2025 to US$ 1912 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
LP Information, Inc. (LPI) ' newest research report, the ?Furmonertinib Mesylate Industry Forecast? looks at past sales and reviews total world Furmonertinib Mesylate sales in 2025, providing a comprehensive analysis by region and market sector of projected Furmonertinib Mesylate sales for 2026 through 2032. With Furmonertinib Mesylate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Furmonertinib Mesylate industry.
This Insight Report provides a comprehensive analysis of the global Furmonertinib Mesylate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Furmonertinib Mesylate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Furmonertinib Mesylate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Furmonertinib Mesylate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Furmonertinib Mesylate.
This report presents a comprehensive overview, market shares, and growth opportunities of Furmonertinib Mesylate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Furmonertinib Mesylate market?
What factors are driving Furmonertinib Mesylate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Furmonertinib Mesylate market opportunities vary by end market size?
How does Furmonertinib Mesylate break out by Type, by Application?
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
LP Information, Inc. (LPI) ' newest research report, the ?Furmonertinib Mesylate Industry Forecast? looks at past sales and reviews total world Furmonertinib Mesylate sales in 2025, providing a comprehensive analysis by region and market sector of projected Furmonertinib Mesylate sales for 2026 through 2032. With Furmonertinib Mesylate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Furmonertinib Mesylate industry.
This Insight Report provides a comprehensive analysis of the global Furmonertinib Mesylate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Furmonertinib Mesylate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Furmonertinib Mesylate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Furmonertinib Mesylate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Furmonertinib Mesylate.
This report presents a comprehensive overview, market shares, and growth opportunities of Furmonertinib Mesylate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 40 mg
- 80 mg
- Hospital
- Retail
- Online
- Non-small Cell Lung Cancer (NSCLC) Treatment
- Patients With Central Nervous System Metastases
- First-line and Later-line Targeted Therapy
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Allist Pharmaceuticals
- Jiangsu Allist Biopharmaceutical
- TargetMol
- MedChemExpress
What is the 10-year outlook for the global Furmonertinib Mesylate market?
What factors are driving Furmonertinib Mesylate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Furmonertinib Mesylate market opportunities vary by end market size?
How does Furmonertinib Mesylate break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Furmonertinib Mesylate Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Furmonertinib Mesylate by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Furmonertinib Mesylate by Country/Region, 2021, 2025 & 2032
2.2 Furmonertinib Mesylate Segment by Type
2.2.1 40 mg
2.2.2 80 mg
2.2.3 Furmonertinib Mesylate Sales by Type
2.2.3.1 Global Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
2.2.3.2 Global Furmonertinib Mesylate Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Furmonertinib Mesylate Sale Price by Type (2021-2026)
2.3 Furmonertinib Mesylate Segment by Sales Channels
2.3.1 Hospital
2.3.2 Retail
2.3.3 Online
2.3.4 Furmonertinib Mesylate Sales by Sales Channels
2.3.4.1 Global Furmonertinib Mesylate Sales Market Share by Sales Channels (2021-2026)
2.3.4.2 Global Furmonertinib Mesylate Revenue and Market Share by Sales Channels (2021-2026)
2.3.4.3 Global Furmonertinib Mesylate Sale Price by Sales Channels (2021-2026)
2.4 Furmonertinib Mesylate Segment by Application
2.4.1 Non-small Cell Lung Cancer (NSCLC) Treatment
2.4.2 Patients With Central Nervous System Metastases
2.4.3 First-line and Later-line Targeted Therapy
2.4.4 Others
2.4.5 Furmonertinib Mesylate Sales by Application
2.4.5.1 Global Furmonertinib Mesylate Sale Market Share by Application (2021-2026)
2.4.5.2 Global Furmonertinib Mesylate Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global Furmonertinib Mesylate Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Furmonertinib Mesylate Breakdown Data by Company
3.1.1 Global Furmonertinib Mesylate Annual Sales by Company (2021-2026)
3.1.2 Global Furmonertinib Mesylate Sales Market Share by Company (2021-2026)
3.2 Global Furmonertinib Mesylate Annual Revenue by Company (2021-2026)
3.2.1 Global Furmonertinib Mesylate Revenue by Company (2021-2026)
3.2.2 Global Furmonertinib Mesylate Revenue Market Share by Company (2021-2026)
3.3 Global Furmonertinib Mesylate Sale Price by Company
3.4 Key Manufacturers Furmonertinib Mesylate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Furmonertinib Mesylate Product Location Distribution
3.4.2 Players Furmonertinib Mesylate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FURMONERTINIB MESYLATE BY GEOGRAPHIC REGION
4.1 World Historic Furmonertinib Mesylate Market Size by Geographic Region (2021-2026)
4.1.1 Global Furmonertinib Mesylate Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Furmonertinib Mesylate Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Furmonertinib Mesylate Market Size by Country/Region (2021-2026)
4.2.1 Global Furmonertinib Mesylate Annual Sales by Country/Region (2021-2026)
4.2.2 Global Furmonertinib Mesylate Annual Revenue by Country/Region (2021-2026)
4.3 Americas Furmonertinib Mesylate Sales Growth
4.4 APAC Furmonertinib Mesylate Sales Growth
4.5 Europe Furmonertinib Mesylate Sales Growth
4.6 Middle East & Africa Furmonertinib Mesylate Sales Growth
5 AMERICAS
5.1 Americas Furmonertinib Mesylate Sales by Country
5.1.1 Americas Furmonertinib Mesylate Sales by Country (2021-2026)
5.1.2 Americas Furmonertinib Mesylate Revenue by Country (2021-2026)
5.2 Americas Furmonertinib Mesylate Sales by Type (2021-2026)
5.3 Americas Furmonertinib Mesylate Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Furmonertinib Mesylate Sales by Region
6.1.1 APAC Furmonertinib Mesylate Sales by Region (2021-2026)
6.1.2 APAC Furmonertinib Mesylate Revenue by Region (2021-2026)
6.2 APAC Furmonertinib Mesylate Sales by Type (2021-2026)
6.3 APAC Furmonertinib Mesylate Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Furmonertinib Mesylate by Country
7.1.1 Europe Furmonertinib Mesylate Sales by Country (2021-2026)
7.1.2 Europe Furmonertinib Mesylate Revenue by Country (2021-2026)
7.2 Europe Furmonertinib Mesylate Sales by Type (2021-2026)
7.3 Europe Furmonertinib Mesylate Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Furmonertinib Mesylate by Country
8.1.1 Middle East & Africa Furmonertinib Mesylate Sales by Country (2021-2026)
8.1.2 Middle East & Africa Furmonertinib Mesylate Revenue by Country (2021-2026)
8.2 Middle East & Africa Furmonertinib Mesylate Sales by Type (2021-2026)
8.3 Middle East & Africa Furmonertinib Mesylate Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Furmonertinib Mesylate
10.3 Manufacturing Process Analysis of Furmonertinib Mesylate
10.4 Industry Chain Structure of Furmonertinib Mesylate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Furmonertinib Mesylate Distributors
11.3 Furmonertinib Mesylate Customer
12 WORLD FORECAST REVIEW FOR FURMONERTINIB MESYLATE BY GEOGRAPHIC REGION
12.1 Global Furmonertinib Mesylate Market Size Forecast by Region
12.1.1 Global Furmonertinib Mesylate Forecast by Region (2027-2032)
12.1.2 Global Furmonertinib Mesylate Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Furmonertinib Mesylate Forecast by Type (2027-2032)
12.7 Global Furmonertinib Mesylate Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Allist Pharmaceuticals
13.1.1 Allist Pharmaceuticals Company Information
13.1.2 Allist Pharmaceuticals Furmonertinib Mesylate Product Portfolios and Specifications
13.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Allist Pharmaceuticals Main Business Overview
13.1.5 Allist Pharmaceuticals Latest Developments
13.2 Jiangsu Allist Biopharmaceutical
13.2.1 Jiangsu Allist Biopharmaceutical Company Information
13.2.2 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product Portfolios and Specifications
13.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Jiangsu Allist Biopharmaceutical Main Business Overview
13.2.5 Jiangsu Allist Biopharmaceutical Latest Developments
13.3 TargetMol
13.3.1 TargetMol Company Information
13.3.2 TargetMol Furmonertinib Mesylate Product Portfolios and Specifications
13.3.3 TargetMol Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 TargetMol Main Business Overview
13.3.5 TargetMol Latest Developments
13.4 MedChemExpress
13.4.1 MedChemExpress Company Information
13.4.2 MedChemExpress Furmonertinib Mesylate Product Portfolios and Specifications
13.4.3 MedChemExpress Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 MedChemExpress Main Business Overview
13.4.5 MedChemExpress Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Furmonertinib Mesylate Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Furmonertinib Mesylate by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Furmonertinib Mesylate by Country/Region, 2021, 2025 & 2032
2.2 Furmonertinib Mesylate Segment by Type
2.2.1 40 mg
2.2.2 80 mg
2.2.3 Furmonertinib Mesylate Sales by Type
2.2.3.1 Global Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
2.2.3.2 Global Furmonertinib Mesylate Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Furmonertinib Mesylate Sale Price by Type (2021-2026)
2.3 Furmonertinib Mesylate Segment by Sales Channels
2.3.1 Hospital
2.3.2 Retail
2.3.3 Online
2.3.4 Furmonertinib Mesylate Sales by Sales Channels
2.3.4.1 Global Furmonertinib Mesylate Sales Market Share by Sales Channels (2021-2026)
2.3.4.2 Global Furmonertinib Mesylate Revenue and Market Share by Sales Channels (2021-2026)
2.3.4.3 Global Furmonertinib Mesylate Sale Price by Sales Channels (2021-2026)
2.4 Furmonertinib Mesylate Segment by Application
2.4.1 Non-small Cell Lung Cancer (NSCLC) Treatment
2.4.2 Patients With Central Nervous System Metastases
2.4.3 First-line and Later-line Targeted Therapy
2.4.4 Others
2.4.5 Furmonertinib Mesylate Sales by Application
2.4.5.1 Global Furmonertinib Mesylate Sale Market Share by Application (2021-2026)
2.4.5.2 Global Furmonertinib Mesylate Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global Furmonertinib Mesylate Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Furmonertinib Mesylate Breakdown Data by Company
3.1.1 Global Furmonertinib Mesylate Annual Sales by Company (2021-2026)
3.1.2 Global Furmonertinib Mesylate Sales Market Share by Company (2021-2026)
3.2 Global Furmonertinib Mesylate Annual Revenue by Company (2021-2026)
3.2.1 Global Furmonertinib Mesylate Revenue by Company (2021-2026)
3.2.2 Global Furmonertinib Mesylate Revenue Market Share by Company (2021-2026)
3.3 Global Furmonertinib Mesylate Sale Price by Company
3.4 Key Manufacturers Furmonertinib Mesylate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Furmonertinib Mesylate Product Location Distribution
3.4.2 Players Furmonertinib Mesylate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FURMONERTINIB MESYLATE BY GEOGRAPHIC REGION
4.1 World Historic Furmonertinib Mesylate Market Size by Geographic Region (2021-2026)
4.1.1 Global Furmonertinib Mesylate Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Furmonertinib Mesylate Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Furmonertinib Mesylate Market Size by Country/Region (2021-2026)
4.2.1 Global Furmonertinib Mesylate Annual Sales by Country/Region (2021-2026)
4.2.2 Global Furmonertinib Mesylate Annual Revenue by Country/Region (2021-2026)
4.3 Americas Furmonertinib Mesylate Sales Growth
4.4 APAC Furmonertinib Mesylate Sales Growth
4.5 Europe Furmonertinib Mesylate Sales Growth
4.6 Middle East & Africa Furmonertinib Mesylate Sales Growth
5 AMERICAS
5.1 Americas Furmonertinib Mesylate Sales by Country
5.1.1 Americas Furmonertinib Mesylate Sales by Country (2021-2026)
5.1.2 Americas Furmonertinib Mesylate Revenue by Country (2021-2026)
5.2 Americas Furmonertinib Mesylate Sales by Type (2021-2026)
5.3 Americas Furmonertinib Mesylate Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Furmonertinib Mesylate Sales by Region
6.1.1 APAC Furmonertinib Mesylate Sales by Region (2021-2026)
6.1.2 APAC Furmonertinib Mesylate Revenue by Region (2021-2026)
6.2 APAC Furmonertinib Mesylate Sales by Type (2021-2026)
6.3 APAC Furmonertinib Mesylate Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Furmonertinib Mesylate by Country
7.1.1 Europe Furmonertinib Mesylate Sales by Country (2021-2026)
7.1.2 Europe Furmonertinib Mesylate Revenue by Country (2021-2026)
7.2 Europe Furmonertinib Mesylate Sales by Type (2021-2026)
7.3 Europe Furmonertinib Mesylate Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Furmonertinib Mesylate by Country
8.1.1 Middle East & Africa Furmonertinib Mesylate Sales by Country (2021-2026)
8.1.2 Middle East & Africa Furmonertinib Mesylate Revenue by Country (2021-2026)
8.2 Middle East & Africa Furmonertinib Mesylate Sales by Type (2021-2026)
8.3 Middle East & Africa Furmonertinib Mesylate Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Furmonertinib Mesylate
10.3 Manufacturing Process Analysis of Furmonertinib Mesylate
10.4 Industry Chain Structure of Furmonertinib Mesylate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Furmonertinib Mesylate Distributors
11.3 Furmonertinib Mesylate Customer
12 WORLD FORECAST REVIEW FOR FURMONERTINIB MESYLATE BY GEOGRAPHIC REGION
12.1 Global Furmonertinib Mesylate Market Size Forecast by Region
12.1.1 Global Furmonertinib Mesylate Forecast by Region (2027-2032)
12.1.2 Global Furmonertinib Mesylate Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Furmonertinib Mesylate Forecast by Type (2027-2032)
12.7 Global Furmonertinib Mesylate Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Allist Pharmaceuticals
13.1.1 Allist Pharmaceuticals Company Information
13.1.2 Allist Pharmaceuticals Furmonertinib Mesylate Product Portfolios and Specifications
13.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Allist Pharmaceuticals Main Business Overview
13.1.5 Allist Pharmaceuticals Latest Developments
13.2 Jiangsu Allist Biopharmaceutical
13.2.1 Jiangsu Allist Biopharmaceutical Company Information
13.2.2 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product Portfolios and Specifications
13.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Jiangsu Allist Biopharmaceutical Main Business Overview
13.2.5 Jiangsu Allist Biopharmaceutical Latest Developments
13.3 TargetMol
13.3.1 TargetMol Company Information
13.3.2 TargetMol Furmonertinib Mesylate Product Portfolios and Specifications
13.3.3 TargetMol Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 TargetMol Main Business Overview
13.3.5 TargetMol Latest Developments
13.4 MedChemExpress
13.4.1 MedChemExpress Company Information
13.4.2 MedChemExpress Furmonertinib Mesylate Product Portfolios and Specifications
13.4.3 MedChemExpress Furmonertinib Mesylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 MedChemExpress Main Business Overview
13.4.5 MedChemExpress Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Furmonertinib Mesylate Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Furmonertinib Mesylate Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 40 mg
Table 4. Major Players of 80 mg
Table 5. Global Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 6. Global Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Table 7. Global Furmonertinib Mesylate Revenue by Type (2021-2026) & ($ million)
Table 8. Global Furmonertinib Mesylate Revenue Market Share by Type (2021-2026)
Table 9. Global Furmonertinib Mesylate Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Hospital
Table 11. Major Players of Retail
Table 12. Major Players of Online
Table 13. Global Furmonertinib Mesylate Sales by Sales Channels (2021-2026) & (Units)
Table 14. Global Furmonertinib Mesylate Sales Market Share by Sales Channels (2021-2026)
Table 15. Global Furmonertinib Mesylate Revenue by Sales Channels (2021-2026) & ($ million)
Table 16. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels (2021-2026)
Table 17. Global Furmonertinib Mesylate Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 18. Major Players ofTablets
Table 19. Major Players of Powder
Table 20. Global Furmonertinib Mesylate Sale by Application (2021-2026) & (Units)
Table 21. Global Furmonertinib Mesylate Sale Market Share by Application (2021-2026)
Table 22. Global Furmonertinib Mesylate Revenue by Application (2021-2026) & ($ million)
Table 23. Global Furmonertinib Mesylate Revenue Market Share by Application (2021-2026)
Table 24. Global Furmonertinib Mesylate Sale Price by Application (2021-2026) & (US$/Unit)
Table 25. Global Furmonertinib Mesylate Sales by Company (2021-2026) & (Units)
Table 26. Global Furmonertinib Mesylate Sales Market Share by Company (2021-2026)
Table 27. Global Furmonertinib Mesylate Revenue by Company (2021-2026) & ($ millions)
Table 28. Global Furmonertinib Mesylate Revenue Market Share by Company (2021-2026)
Table 29. Global Furmonertinib Mesylate Sale Price by Company (2021-2026) & (US$/Unit)
Table 30. Key Manufacturers Furmonertinib Mesylate Producing Area Distribution and Sales Area
Table 31. Players Furmonertinib Mesylate Products Offered
Table 32. Furmonertinib Mesylate Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 33. New Products and Potential Entrants
Table 34. Market M&A Activity & Strategy
Table 35. Global Furmonertinib Mesylate Sales by Geographic Region (2021-2026) & (Units)
Table 36. Global Furmonertinib Mesylate Sales Market Share Geographic Region (2021-2026)
Table 37. Global Furmonertinib Mesylate Revenue by Geographic Region (2021-2026) & ($ millions)
Table 38. Global Furmonertinib Mesylate Revenue Market Share by Geographic Region (2021-2026)
Table 39. Global Furmonertinib Mesylate Sales by Country/Region (2021-2026) & (Units)
Table 40. Global Furmonertinib Mesylate Sales Market Share by Country/Region (2021-2026)
Table 41. Global Furmonertinib Mesylate Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Furmonertinib Mesylate Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 44. Americas Furmonertinib Mesylate Sales Market Share by Country (2021-2026)
Table 45. Americas Furmonertinib Mesylate Revenue by Country (2021-2026) & ($ millions)
Table 46. Americas Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 47. Americas Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 48. APAC Furmonertinib Mesylate Sales by Region (2021-2026) & (Units)
Table 49. APAC Furmonertinib Mesylate Sales Market Share by Region (2021-2026)
Table 50. APAC Furmonertinib Mesylate Revenue by Region (2021-2026) & ($ millions)
Table 51. APAC Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 52. APAC Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 53. Europe Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 54. Europe Furmonertinib Mesylate Revenue by Country (2021-2026) & ($ millions)
Table 55. Europe Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 56. Europe Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 57. Middle East & Africa Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 58. Middle East & Africa Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Table 59. Middle East & Africa Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 60. Middle East & Africa Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 61. Key Market Drivers & Growth Opportunities of Furmonertinib Mesylate
Table 62. Key Market Challenges & Risks of Furmonertinib Mesylate
Table 63. Key Industry Trends of Furmonertinib Mesylate
Table 64. Furmonertinib Mesylate Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Furmonertinib Mesylate Distributors List
Table 67. Furmonertinib Mesylate Customer List
Table 68. Global Furmonertinib Mesylate Sales Forecast by Region (2027-2032) & (Units)
Table 69. Global Furmonertinib Mesylate Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Americas Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 71. Americas Furmonertinib Mesylate Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. APAC Furmonertinib Mesylate Sales Forecast by Region (2027-2032) & (Units)
Table 73. APAC Furmonertinib Mesylate Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Europe Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 75. Europe Furmonertinib Mesylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. Middle East & Africa Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 77. Middle East & Africa Furmonertinib Mesylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Global Furmonertinib Mesylate Sales Forecast by Type (2027-2032) & (Units)
Table 79. Global Furmonertinib Mesylate Revenue Forecast by Type (2027-2032) & ($ millions)
Table 80. Global Furmonertinib Mesylate Sales Forecast by Application (2027-2032) & (Units)
Table 81. Global Furmonertinib Mesylate Revenue Forecast by Application (2027-2032) & ($ millions)
Table 82. Allist Pharmaceuticals Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 83. Allist Pharmaceuticals Furmonertinib Mesylate Product Portfolios and Specifications
Table 84. Allist Pharmaceuticals Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Allist Pharmaceuticals Main Business
Table 86. Allist Pharmaceuticals Latest Developments
Table 87. Jiangsu Allist Biopharmaceutical Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 88. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product Portfolios and Specifications
Table 89. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Jiangsu Allist Biopharmaceutical Main Business
Table 91. Jiangsu Allist Biopharmaceutical Latest Developments
Table 92. TargetMol Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 93. TargetMol Furmonertinib Mesylate Product Portfolios and Specifications
Table 94. TargetMol Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. TargetMol Main Business
Table 96. TargetMol Latest Developments
Table 97. MedChemExpress Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 98. MedChemExpress Furmonertinib Mesylate Product Portfolios and Specifications
Table 99. MedChemExpress Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. MedChemExpress Main Business
Table 101. MedChemExpress Latest Developments
Table 1. Furmonertinib Mesylate Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Furmonertinib Mesylate Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 40 mg
Table 4. Major Players of 80 mg
Table 5. Global Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 6. Global Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Table 7. Global Furmonertinib Mesylate Revenue by Type (2021-2026) & ($ million)
Table 8. Global Furmonertinib Mesylate Revenue Market Share by Type (2021-2026)
Table 9. Global Furmonertinib Mesylate Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Hospital
Table 11. Major Players of Retail
Table 12. Major Players of Online
Table 13. Global Furmonertinib Mesylate Sales by Sales Channels (2021-2026) & (Units)
Table 14. Global Furmonertinib Mesylate Sales Market Share by Sales Channels (2021-2026)
Table 15. Global Furmonertinib Mesylate Revenue by Sales Channels (2021-2026) & ($ million)
Table 16. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels (2021-2026)
Table 17. Global Furmonertinib Mesylate Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 18. Major Players ofTablets
Table 19. Major Players of Powder
Table 20. Global Furmonertinib Mesylate Sale by Application (2021-2026) & (Units)
Table 21. Global Furmonertinib Mesylate Sale Market Share by Application (2021-2026)
Table 22. Global Furmonertinib Mesylate Revenue by Application (2021-2026) & ($ million)
Table 23. Global Furmonertinib Mesylate Revenue Market Share by Application (2021-2026)
Table 24. Global Furmonertinib Mesylate Sale Price by Application (2021-2026) & (US$/Unit)
Table 25. Global Furmonertinib Mesylate Sales by Company (2021-2026) & (Units)
Table 26. Global Furmonertinib Mesylate Sales Market Share by Company (2021-2026)
Table 27. Global Furmonertinib Mesylate Revenue by Company (2021-2026) & ($ millions)
Table 28. Global Furmonertinib Mesylate Revenue Market Share by Company (2021-2026)
Table 29. Global Furmonertinib Mesylate Sale Price by Company (2021-2026) & (US$/Unit)
Table 30. Key Manufacturers Furmonertinib Mesylate Producing Area Distribution and Sales Area
Table 31. Players Furmonertinib Mesylate Products Offered
Table 32. Furmonertinib Mesylate Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 33. New Products and Potential Entrants
Table 34. Market M&A Activity & Strategy
Table 35. Global Furmonertinib Mesylate Sales by Geographic Region (2021-2026) & (Units)
Table 36. Global Furmonertinib Mesylate Sales Market Share Geographic Region (2021-2026)
Table 37. Global Furmonertinib Mesylate Revenue by Geographic Region (2021-2026) & ($ millions)
Table 38. Global Furmonertinib Mesylate Revenue Market Share by Geographic Region (2021-2026)
Table 39. Global Furmonertinib Mesylate Sales by Country/Region (2021-2026) & (Units)
Table 40. Global Furmonertinib Mesylate Sales Market Share by Country/Region (2021-2026)
Table 41. Global Furmonertinib Mesylate Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Furmonertinib Mesylate Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 44. Americas Furmonertinib Mesylate Sales Market Share by Country (2021-2026)
Table 45. Americas Furmonertinib Mesylate Revenue by Country (2021-2026) & ($ millions)
Table 46. Americas Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 47. Americas Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 48. APAC Furmonertinib Mesylate Sales by Region (2021-2026) & (Units)
Table 49. APAC Furmonertinib Mesylate Sales Market Share by Region (2021-2026)
Table 50. APAC Furmonertinib Mesylate Revenue by Region (2021-2026) & ($ millions)
Table 51. APAC Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 52. APAC Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 53. Europe Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 54. Europe Furmonertinib Mesylate Revenue by Country (2021-2026) & ($ millions)
Table 55. Europe Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 56. Europe Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 57. Middle East & Africa Furmonertinib Mesylate Sales by Country (2021-2026) & (Units)
Table 58. Middle East & Africa Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Table 59. Middle East & Africa Furmonertinib Mesylate Sales by Type (2021-2026) & (Units)
Table 60. Middle East & Africa Furmonertinib Mesylate Sales by Application (2021-2026) & (Units)
Table 61. Key Market Drivers & Growth Opportunities of Furmonertinib Mesylate
Table 62. Key Market Challenges & Risks of Furmonertinib Mesylate
Table 63. Key Industry Trends of Furmonertinib Mesylate
Table 64. Furmonertinib Mesylate Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Furmonertinib Mesylate Distributors List
Table 67. Furmonertinib Mesylate Customer List
Table 68. Global Furmonertinib Mesylate Sales Forecast by Region (2027-2032) & (Units)
Table 69. Global Furmonertinib Mesylate Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Americas Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 71. Americas Furmonertinib Mesylate Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. APAC Furmonertinib Mesylate Sales Forecast by Region (2027-2032) & (Units)
Table 73. APAC Furmonertinib Mesylate Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Europe Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 75. Europe Furmonertinib Mesylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. Middle East & Africa Furmonertinib Mesylate Sales Forecast by Country (2027-2032) & (Units)
Table 77. Middle East & Africa Furmonertinib Mesylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Global Furmonertinib Mesylate Sales Forecast by Type (2027-2032) & (Units)
Table 79. Global Furmonertinib Mesylate Revenue Forecast by Type (2027-2032) & ($ millions)
Table 80. Global Furmonertinib Mesylate Sales Forecast by Application (2027-2032) & (Units)
Table 81. Global Furmonertinib Mesylate Revenue Forecast by Application (2027-2032) & ($ millions)
Table 82. Allist Pharmaceuticals Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 83. Allist Pharmaceuticals Furmonertinib Mesylate Product Portfolios and Specifications
Table 84. Allist Pharmaceuticals Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Allist Pharmaceuticals Main Business
Table 86. Allist Pharmaceuticals Latest Developments
Table 87. Jiangsu Allist Biopharmaceutical Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 88. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product Portfolios and Specifications
Table 89. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Jiangsu Allist Biopharmaceutical Main Business
Table 91. Jiangsu Allist Biopharmaceutical Latest Developments
Table 92. TargetMol Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 93. TargetMol Furmonertinib Mesylate Product Portfolios and Specifications
Table 94. TargetMol Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. TargetMol Main Business
Table 96. TargetMol Latest Developments
Table 97. MedChemExpress Basic Information, Furmonertinib Mesylate Manufacturing Base, Sales Area and Its Competitors
Table 98. MedChemExpress Furmonertinib Mesylate Product Portfolios and Specifications
Table 99. MedChemExpress Furmonertinib Mesylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. MedChemExpress Main Business
Table 101. MedChemExpress Latest Developments
LIST OF FIGURES
Figure 1. Picture of Furmonertinib Mesylate
Figure 2. Furmonertinib Mesylate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Furmonertinib Mesylate Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Furmonertinib Mesylate Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Furmonertinib Mesylate Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Furmonertinib Mesylate Sales Market Share by Country/Region (2025)
Figure 10. Furmonertinib Mesylate Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 40 mg
Figure 12. Product Picture of 80 mg
Figure 13. Global Furmonertinib Mesylate Sales Market Share by Type in 2026
Figure 14. Global Furmonertinib Mesylate Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Retail
Figure 17. Product Picture of Online
Figure 18. Global Furmonertinib Mesylate Sales Market Share by Sales Channels in 2026
Figure 19. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels (2021-2026)
Figure 20. Product Picture ofTablets
Figure 21. Product Picture of Powder
Figure 22. Furmonertinib Mesylate Consumed in Non-small Cell Lung Cancer (NSCLC) Treatment
Figure 23. Global Furmonertinib Mesylate Market: Non-small Cell Lung Cancer (NSCLC) Treatment (2021-2026) & (Units)
Figure 24. Furmonertinib Mesylate Consumed in Patients With Central Nervous System Metastases
Figure 25. Global Furmonertinib Mesylate Market: Patients With Central Nervous System Metastases (2021-2026) & (Units)
Figure 26. Furmonertinib Mesylate Consumed in First-line and Later-line Targeted Therapy
Figure 27. Global Furmonertinib Mesylate Market: First-line and Later-line Targeted Therapy (2021-2026) & (Units)
Figure 28. Furmonertinib Mesylate Consumed in Others
Figure 29. Global Furmonertinib Mesylate Market: Others (2021-2026) & (Units)
Figure 30. Global Furmonertinib Mesylate Sale Market Share by Application (2025)
Figure 31. Global Furmonertinib Mesylate Revenue Market Share by Application in 2025
Figure 32. Furmonertinib Mesylate Sales by Company in 2025 (Units)
Figure 33. Global Furmonertinib Mesylate Sales Market Share by Company in 2025
Figure 34. Furmonertinib Mesylate Revenue by Company in 2025 ($ millions)
Figure 35. Global Furmonertinib Mesylate Revenue Market Share by Company in 2025
Figure 36. Global Furmonertinib Mesylate Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Furmonertinib Mesylate Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 39. Americas Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 40. APAC Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 41. APAC Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 42. Europe Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 43. Europe Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 45. Middle East & Africa Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 46. Americas Furmonertinib Mesylate Sales Market Share by Country in 2025
Figure 47. Americas Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Figure 48. Americas Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 49. Americas Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 50. United States Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Furmonertinib Mesylate Sales Market Share by Region in 2025
Figure 55. APAC Furmonertinib Mesylate Revenue Market Share by Region (2021-2026)
Figure 56. APAC Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 57. APAC Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 58. China Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 62. India Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Furmonertinib Mesylate Sales Market Share by Country in 2025
Figure 66. Europe Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Figure 67. Europe Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 68. Europe Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 69. Germany Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 70. France Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 77. Egypt Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Furmonertinib Mesylate in 2026
Figure 83. Manufacturing Process Analysis of Furmonertinib Mesylate
Figure 84. Industry Chain Structure of Furmonertinib Mesylate
Figure 85. Channels of Distribution
Figure 86. Global Furmonertinib Mesylate Sales Market Forecast by Region (2027-2032)
Figure 87. Global Furmonertinib Mesylate Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Furmonertinib Mesylate Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Furmonertinib Mesylate Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Furmonertinib Mesylate Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Furmonertinib Mesylate Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Furmonertinib Mesylate
Figure 2. Furmonertinib Mesylate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Furmonertinib Mesylate Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Furmonertinib Mesylate Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Furmonertinib Mesylate Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Furmonertinib Mesylate Sales Market Share by Country/Region (2025)
Figure 10. Furmonertinib Mesylate Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 40 mg
Figure 12. Product Picture of 80 mg
Figure 13. Global Furmonertinib Mesylate Sales Market Share by Type in 2026
Figure 14. Global Furmonertinib Mesylate Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Retail
Figure 17. Product Picture of Online
Figure 18. Global Furmonertinib Mesylate Sales Market Share by Sales Channels in 2026
Figure 19. Global Furmonertinib Mesylate Revenue Market Share by Sales Channels (2021-2026)
Figure 20. Product Picture ofTablets
Figure 21. Product Picture of Powder
Figure 22. Furmonertinib Mesylate Consumed in Non-small Cell Lung Cancer (NSCLC) Treatment
Figure 23. Global Furmonertinib Mesylate Market: Non-small Cell Lung Cancer (NSCLC) Treatment (2021-2026) & (Units)
Figure 24. Furmonertinib Mesylate Consumed in Patients With Central Nervous System Metastases
Figure 25. Global Furmonertinib Mesylate Market: Patients With Central Nervous System Metastases (2021-2026) & (Units)
Figure 26. Furmonertinib Mesylate Consumed in First-line and Later-line Targeted Therapy
Figure 27. Global Furmonertinib Mesylate Market: First-line and Later-line Targeted Therapy (2021-2026) & (Units)
Figure 28. Furmonertinib Mesylate Consumed in Others
Figure 29. Global Furmonertinib Mesylate Market: Others (2021-2026) & (Units)
Figure 30. Global Furmonertinib Mesylate Sale Market Share by Application (2025)
Figure 31. Global Furmonertinib Mesylate Revenue Market Share by Application in 2025
Figure 32. Furmonertinib Mesylate Sales by Company in 2025 (Units)
Figure 33. Global Furmonertinib Mesylate Sales Market Share by Company in 2025
Figure 34. Furmonertinib Mesylate Revenue by Company in 2025 ($ millions)
Figure 35. Global Furmonertinib Mesylate Revenue Market Share by Company in 2025
Figure 36. Global Furmonertinib Mesylate Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Furmonertinib Mesylate Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 39. Americas Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 40. APAC Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 41. APAC Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 42. Europe Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 43. Europe Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Furmonertinib Mesylate Sales 2021-2026 (Units)
Figure 45. Middle East & Africa Furmonertinib Mesylate Revenue 2021-2026 ($ millions)
Figure 46. Americas Furmonertinib Mesylate Sales Market Share by Country in 2025
Figure 47. Americas Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Figure 48. Americas Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 49. Americas Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 50. United States Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Furmonertinib Mesylate Sales Market Share by Region in 2025
Figure 55. APAC Furmonertinib Mesylate Revenue Market Share by Region (2021-2026)
Figure 56. APAC Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 57. APAC Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 58. China Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 62. India Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Furmonertinib Mesylate Sales Market Share by Country in 2025
Figure 66. Europe Furmonertinib Mesylate Revenue Market Share by Country (2021-2026)
Figure 67. Europe Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 68. Europe Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 69. Germany Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 70. France Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Furmonertinib Mesylate Sales Market Share by Application (2021-2026)
Figure 77. Egypt Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Furmonertinib Mesylate Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Furmonertinib Mesylate in 2026
Figure 83. Manufacturing Process Analysis of Furmonertinib Mesylate
Figure 84. Industry Chain Structure of Furmonertinib Mesylate
Figure 85. Channels of Distribution
Figure 86. Global Furmonertinib Mesylate Sales Market Forecast by Region (2027-2032)
Figure 87. Global Furmonertinib Mesylate Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Furmonertinib Mesylate Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Furmonertinib Mesylate Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Furmonertinib Mesylate Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Furmonertinib Mesylate Revenue Market Share Forecast by Application (2027-2032)
